Claims
- 1. A method of producing a polyketide, comprising culturing a cell under conditions under which the cell produces the polyketide, wherein said cell comprises a recombinant polynucleotide that hybridises under stringent conditions to the polyketide synthase-encoding region of SEQ ID NO:1 and/or SEQ ID NO:2 and encodes at least one core polyketide synthase protein, and wherein said cell is unable to make the polyketide in the absence of said recombinant polynucleotide.
- 2. The method of claim 1 wherein the recombinant polynucleotide is an expression vector.
- 3. The cell of claim 1 that is not Streptomyces.
- 4. The cell of claim 1 wherein the polyketide is pro-geldanamycin.
- 5. The cell of claim 4 that produces geldanamycin.
- 6. The cell of claim 4 that produces herbimycin.
- 7. A recombinant host cell comprising one or more expression vectors that drive expression of polyketide synthase enzymes capable of making pro-geldanamycin in the cell, wherein said host cell produces progeldanamycin and wherein said host cell, in the absence of said expression vectors, does not produce progeldanamycin.
- 8. The cell of claim 1 that is not Streptomyces.
- 9. A recombinant DNA molecule encoding a domain of a geldanamycin polyketide synthase (PKS) or a herbimycin PKS.
- 10. The recombinant DNA molecule of claim 9 that encodes one or more modules or polypeptides of a chimeric PKS.
- 11. The recombinant DNA molecule of claim 9 that encodes a module of said geldanamycin PKS or a herbimycin PKS.
- 12. The recombinant DNA molecule of claim 11 comprising an open reading frame (ORF) selected from the group consisting of gdmAI, gdmAII and gdmAIII.
- 13. The recombinant DNA molecule of claim 11 that encodes a modified geldanamycin PKS polypeptide that differs from the geldanamycin PKS by inactivation of at least one geldanamycin PKS domain.
- 14. The recombinant DNA molecule of claim 11 comprising an open reading frame (ORF) selected from the group consisting of hbmAI, hbmAII and hbmAIII.
- 15. The recombinant DNA molecule of claim 14 that encodes a modified herbimycin PKS polypeptide that differs from the native herbimycin PKS by inactivation of at least one herbimycin PKS domain.
- 16. A recombinant DNA molecule encoding a geldanamycin modification enzyme that is involved in the conversion of progeldanamycin to geldanamycin.
- 17. A recombinant DNA molecule encoding a herbimycin modification enzyme that is involved in the conversion of proherbimycin to herbimycin.
- 18. The recombinant DNA molecule of claim 9, that hybridizes under stringent conditions to a nucleic acid having a nucleotide sequence of SEQ. ID NO:1 and/or SEQ. ID NO:2.
- 19. A recombinant DNA expression vector comprising the DNA molecule of claim 9 operably linked to a promoter.
- 20. The expression vector of claim 19 wherein the promoter is derived from a cell other than Streptomyces.
- 21. A host cell comprising a recombinant DNA molecule of claim 9.
- 22. A host cell that expresses at least one domain of a geldanamycin PKS or a herbimycin PKS.
- 23. A host cell comprising a recombinant DNA molecule of claim 12.
- 24. A host cell comprising a recombinant DNA molecule of claim 14.
- 25. A host cell comprising the vector of claim 19.
- 26. The host cell of claim 19 that is an S. hygroscopicus cell.
- 27. The host cell of claim 19 that is not an S. hygroscopicus cell or is not an S. hygroscopicus var. geldanus NRRL 3602 cell.
- 28. A method of producing a polyketide, which method comprises growing the recombinant host cell of claim 23 or 24 under conditions whereby a polyketide synthesized by a PKS comprising a protein encoded by said recombinant DNA molecule is produced in the cell, and, optionally, recovering the synthesized polyketide.
- 29. The method of claim 28 further comprising chemically modifying said polyketide.
- 30. The method of claim 28 further comprising formulating said polyketide for administration to a mammal.
- 31. An isolated polypeptide encoded by the recombinant DNA molecule of claim 9.
- 32. A chimeric PKS that is composed of at least a portion of a geldanamycin PKS and at least a portion of a second PKS for a polyketide other than geldanamycin.
- 33. A chimeric PKS that is composed of at least a portion of a herbimycin PKS and at least a portion of a second PKS for a polyketide other than herbimycin .
- 34. The chimeric PKS of claim 32 or 33 wherein the second PKS is selected from the group consisting of a narbonolide PKS, an oleandolide PKS, a DEBS PKS and a rapamycin PKS.
- 35. A method of producing a polyketide comprising
(a) recombinantly modifying a gene in the geldanamycin PKS gene cluster of a Streptomyces cell comprising said gene cluster to produce a recombinant cell, or obtaining a progeny of said recombinant cell; (b) growing the recombinant cell or progeny under conditions whereby a polyketide other than geldanamycin is synthesized by the cell and, optionally, recovering the synthesized polyketide.
- 36. The method of claim 35 wherein the cell is S. hygroscopicus var. geldanus NRRL 3602.
- 37. The method of claim 35 wherein the cell does not produce geldanamycin.
- 38. A method of producing a polyketide comprising
(a) recombinantly modifying a gene in the herbimycin PKS gene cluster of a Streptomyces cell comprising said gene cluster to produce a recombinant cell, or obtaining a progeny of said recombinant cell; (b) growing the recombinant cell or progeny under conditions whereby a polyketide other than herbimycin is synthesized by the cell and recovering the synthesized polyketide.
- 39. The method of claim 38 wherein the cell is S. hygroscopicus AM-3672.
- 40. The method of claim 38 wherein the cell does not produce herbimycin.
- 41. The method of claim 35 or 38 wherein said modifying comprises:
(a) substitution of a geldanamycin AT domain with an AT domain having a different specificity; (b) inactivation of a domain, wherein said domain is selected from the group consisting of a KS domain, an AT domain, an ACP domain, a KR domain, a DH domain, and an ER domain; or, (c) substitution of KS domain, an ACP domain, a KR domain, a DH domain, or an ER domain with a domain having a different specificity.
- 42. The method of claim 35 further comprising chemically modifying said polyketide.
- 43. The method of claim 35 or claim 42 further comprising formulating said polyketide for administration to a mammal.
- 44. A recombinant DNA molecule comprising one or more open reading frames (ORFs) of SEQ ID NO:3.
- 45. The DNA of claim 44 wherein the ORF comprises basepairs 5263-6345; 6575-7270; 2427-3224; 1364-2413; 3397-3846; 4058-5224; or 428-1252 of SEQ ID NO:3.
- 46. A host cell comprising a recombinant DNA molecule of claim 44.
- 47. A recombinant DNA expression vector comprising the DNA molecule of claim 44 operably linked to a promoter.
- 48. A host cell comprising the vector of claim 47.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional patent application Nos. 60/389,255 (filed Jun. 14, 2002), 60/393,929 (filed Jul. 3, 2002), 60/395,275 (filed Jul. 12, 2002), 60/415,326 (filed Sep. 30, 2002), 60/420,820 (filed Oct. 24, 2002), 60/433,130 (filed Dec. 13, 2002), and is a Continuation-in-Part of U.S. patent application Ser. No. 10/212,962 (filed Aug. 5, 2002). The entire contents of each of these applications is incorporated herein by reference.
Provisional Applications (6)
|
Number |
Date |
Country |
|
60389255 |
Jun 2002 |
US |
|
60393929 |
Jul 2002 |
US |
|
60395275 |
Jul 2002 |
US |
|
60415326 |
Sep 2002 |
US |
|
60420820 |
Oct 2002 |
US |
|
60433130 |
Dec 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10212962 |
Aug 2002 |
US |
Child |
10461194 |
Jun 2003 |
US |